Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Cited In for PubMed (Select 17404349)


Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.

Harris KB, McCarty DJ.

Ther Adv Endocrinol Metab. 2015 Feb;6(1):3-18. doi: 10.1177/2042018814558242. Review.


Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes.

Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC.

J Diabetes Investig. 2014 Sep;5(5):554-62. doi: 10.1111/jdi.12184. Epub 2013 Dec 22.


Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.

Stranges P, Khanderia U.

Ther Adv Drug Saf. 2012 Aug;3(4):185-201. doi: 10.1177/2042098612454290. Review.


Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.

Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, Haber H, Guerrettaz K, Boardman MK.

J Diabetes Investig. 2013 Jan 29;4(1):53-61. doi: 10.1111/j.2040-1124.2012.00238.x. Epub 2012 Sep 14.


Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.

Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T.

J Diabetes Investig. 2011 Nov 30;2(6):448-56. doi: 10.1111/j.2040-1124.2011.00137.x.


Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.

Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman MK, Sowa H.

J Diabetes Investig. 2011 Jun 5;2(3):210-7. doi: 10.1111/j.2040-1124.2010.00084.x.


Assessment of pancreatic β-cell function: review of methods and clinical applications.

Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL.

Curr Diabetes Rev. 2014 Jan;10(1):2-42. Review.


Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.

Arakaki RF, Blevins TC, Wise JK, Liljenquist DR, Jiang HH, Jacobson JG, Martin SA, Jackson JA.

Diabetes Obes Metab. 2014 Jun;16(6):510-8. doi: 10.1111/dom.12242. Epub 2013 Dec 29.


Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.

DeFronzo RA, Eldor R, Abdul-Ghani M.

Diabetes Care. 2013 Aug;36 Suppl 2:S127-38. doi: 10.2337/dcS13-2011. No abstract available.


Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.

Sun F, Yu K, Yang Z, Wu S, Zhang Y, Shi L, Ji L, Zhan S.

Exp Diabetes Res. 2012;2012:230624. doi: 10.1155/2012/230624. Epub 2012 Dec 26. Review.


Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP.

BMJ Open. 2013 Jan 24;3(1). pii: e001986. doi: 10.1136/bmjopen-2012-001986.


Exenatide extended-release; clinical trials, patient preference, and economic considerations.

Doggrell SA.

Patient Prefer Adherence. 2013;7:35-45. doi: 10.2147/PPA.S30627. Epub 2013 Jan 9.


Incretin hormones and the satiation signal.

Holst JJ.

Int J Obes (Lond). 2013 Sep;37(9):1161-8. doi: 10.1038/ijo.2012.208. Epub 2013 Jan 8. Review.


Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.


The evolving world of GLP-1 agonist therapies for type 2 diabetes.

Baynes KC.

Ther Adv Endocrinol Metab. 2010 Apr;1(2):61-7. doi: 10.1177/2042018810375414.


Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.

Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB.

Int J Clin Pract. 2012 Dec;66(12):1147-57. doi: 10.1111/ijcp.12032. Epub 2012 Oct 14. Review.


The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.

Brice KR, Tzefos MK.

Clin Med Insights Endocrinol Diabetes. 2011;4:13-24. doi: 10.4137/CMED.S4086. Epub 2011 Mar 14.


GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.

Meloni AR, DeYoung MB, Lowe C, Parkes DG.

Diabetes Obes Metab. 2013 Jan;15(1):15-27. doi: 10.1111/j.1463-1326.2012.01663.x. Epub 2012 Aug 1. Review.


Alterations in energy balance following exenatide administration.

Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA.

Appl Physiol Nutr Metab. 2012 Oct;37(5):893-9. doi: 10.1139/h2012-068. Epub 2012 Jun 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk